When was PAQ founded?

PAQ was founded in 2020 and raised its 1st funding round within a year of its incorporation.

Where is PAQ located?

PAQ is headquartered in Cambridge, United States. It is registered at 625 Mass Ave. Office 02-146 Cambridge, MA, 02139, USA.

Who is the current CEO of PAQ?

Nan Ji of PAQ. They have also founded 1 company.

How many employees does PAQ have?

As of Feb 28, 2026, the latest employee count at PAQ is 11.

Is PAQ a funded company?

PAQ is a funded company, having raised a total of $111M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on 2020.

When was the latest funding round of PAQ?

PAQ's latest funding was a $***** Series B round on Jan 26, 2026, with participation from 0 investor. Its primary sector is Neurology. In United States, the Neurology sector has seen $2.08B in funding in 2026 to date.

Where does PAQ rank among its competitors?

PAQ ranks 16th amongst 449 active competitors, of which 155 are funded. It stands 8th in terms of total funding among its competitors. The most recent competitor to raise funding was PAQ, which secured $38M in Jan, 2026.

Who are the top competitors of PAQ?

PAQ's top competitors include Alector, Juvenescence and Annexon. Among them, PAQ secured the most recent funding round in January, 2026.

PAQ - 2026 Company Profile, Team, Funding & Competitors

PAQ is a series B company based in Cambridge (United States), founded in 2020 by Nan Ji, Boxun Lu and Huaixiang Hao. It operates as a Developer of small molecule therapeutics for neurodegenerative disease. PAQ has raised $111M in funding from investors like MRLV, Sherpa Healthcare Partners and Bayland Capital. The company has 449 active competitors, including 155 funded and 82 that have exited. Its top competitors include companies like Alector, Juvenescence and Annexon.

Company Details

Developer of small molecule therapeutics for neurodegenerative disease. The company offers autophagosome-tethering compounds that enhances the degradation of disease-causing protein and non-protein targets.

Website: www.paqtx.com
Email ID: *****@paqtx.com
Phone Number: +1 **********
Registered Address: 625 Mass Ave. Office 02-146 Cambridge, MA, 02139, USA

Key Metrics

Founded Year

2020

Location

Cambridge, United States

Stage

Series B

Total Funding

$111M in 4 rounds

Latest Funding Round

Series B, Jan 26, 2026, $*****

Investors

MRLV & 9 more

Ranked

16^th among 449 active competitors

Employee Count

11 as on Feb 28, 2026

Similar Companies

Alector & 559 more

View PAQ's full profile

PAQ is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
PAQ Therapeutics Inc CIN: 85-2211089 , United States, Active	Jul 26, 2020	-	6 (As on Dec 31, 2021)	-

PAQ has raised a total funding of $111M over 4 rounds. Its first funding round was on 2020. PAQ has 10 institutional investors.

Here is the list of recent funding rounds of PAQ:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jan 26, 2026	7435295	Series B	5992115	9321455	8093369	7989425
May 06, 2025	3660356	Series B	8478032	3477311	6418615	Johnson & Johnson Innovation & 3 more
Jul 15, 2021	5195608	Series A	6795707	6854011	Sherpa Healthcare Partners	Huagai Capital & 2 more

Access funding benchmarks and valuations. Sign up today!

View details of PAQ's funding rounds and investors

The founders of PAQ are Nan Ji, Boxun Lu and Huaixiang Hao. Nan Ji is the CEO of PAQ.

Here are the details of PAQ's key team members:

Nan Ji: Co-Founder, President and CEO of PAQ.
Boxun Lu: Co-Founder of PAQ.
Huaixiang Hao: Co-Founder of PAQ.

View details of PAQ's Founder profiles and Board Members

PAQ's employee count trend

PAQ has 11 employees as of Feb 26. Here is PAQ's employee count trend over the years:

Uncover PAQ's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of PAQ include Alector, Juvenescence and Annexon. Here is the list of Top 10 competitors of PAQ, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Alector 2013, San Francisco (United States), Public	Developing immuno-modulatory therapies for dementia and other neurodegenerative disorders	$215M	AbbVie, The Dementia Discovery Fund & 20 others	73/100
2nd	Juvenescence 2017, Dublin (Ireland), Series B	Provider of proprietary ketone ester-based therapeutic drink for age-related disorders and metabolic health	$290M	Ipgl, Foresite Capital & 9 others	68/100
3rd	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, New Enterprise Associates ... & 16 others	67/100
4th	MeiraGTx 2015, New York City (United States), Public	Developer of gene therapies for ocular and neurodegenerative diseases	-	Sanofi, Perceptive Advisors & 5 others	65/100
5th	Axsome Therapeutics 2012, New York City (United States), Public	Developer of therapeutic solutions for the management of CNS disorders	$8.7M	SVB Securities, Collage Venture Partners	65/100
6th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response	$192M	Pfizer Venture Investments, Sofinnova Partners ... & 46 others	63/100
7th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 5 others	63/100
8th	Cognition Therapeutics 2007, Pittsburgh (United States), Public	Developer of small molecule drugs for neurodegenerative diseases	$36.1M	Golden Seeds, iNetworks & 28 others	63/100
9th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
10th	Atalanta Therapeutics 2019, Boston (United States), Series B	Developer of RNAi therapeutics to treat neurodegenerative diseases	$262M	F-Prime Capital, Sanofi Ventures & 7 others	62/100
16th	PAQ 2020, Cambridge (United States), Series B	Developer of small molecule therapeutics for neurodegenerative disease	$111M	MSA Capital, Huagai Capital & 8 others	61/100